albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Acylated GLP-1 receptor agonist | 31-residue synthetic peptide |
| Molecular formula | C187H291N45O59 | established for the free peptide |
| Appearance | White to off-white powder | as supplied before formulation |
| Solubility | Freely soluble in water | aqueous buffers near neutral pH |
| Typical storage | 2 to 8 degrees Celsius, protected from light | powder and solution forms differ in shelf life |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Balmer Lawrie & Co. Ltd. (BL) is an Indian central public sector undertaking and a conglomerate under the Ministry of Petroleum and Natural Gas, Government of India. It is classified as a category-I Miniratna company. Originally founded in 1867 by George Stephen Balmer and Alexander Lawrie in Calcutta, British India, the conglomerate has eight strategic business units, four joint ventures in India and abroad, and a subsidiary in India.
The team won the 1998 CARICOM Men's Basketball Championship, held at the Civic Centre in Belize City, and subsequently participated in the 1999 Centrobasquet Tournament in Havana. The national team finished seventh of eight teams after winning only 1 game despite playing close all the way. In a return engagement at the 2000 CARICOM championship in Barbados, Belize placed fourth. Shortly thereafter, Belize moved to the Central American region and won the Central American Games championship in 2001. The team has failed to duplicate this success finishing with a 2–4 record in the 2006 COCABA championship. The team finished second in the 2009 COCABA tournament in Cancun, Mexico where it went 3–0 in group play. Belize won its opening match in the Centrobasquet Tournament, 2010, defeating Trinidad and Tobago, but lost badly to Mexico in a rematch of the COCABA final. A tough win over Cuba set Belize in position to advance, but they fell to Puerto Rico in their final match and failed to qualify. Chess is played in Belize, with the country having national governing bodies for the sport: Belize Chess Federation and Belize National Youth Chess Foundation.
=== Laboratory studies === Laboratory studies are employed when there are suspicions of autoimmune causes, infection or malignancy. Laboratory testing may include white blood cell (WBC) count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
Sources: en.wikipedia.org
=== Recurring === Brittany Inge as Ashley James, Patricia's eldest child from her previous relationship as a teenager who is a therapist. She and her mother have a rocky relationship toward the beginning of the show due to their disagreement over Ashley being a lesbian, but Pat grows to accept her identity. Reagan Pasternak as Elizabeth Patterson, the PTO chair and best friend to Pat and Denise. Well-to-do with a past of her own, she is also Ryan’s mom. Elizabeth is initially portrayed as the straight-laced opposite of her new neighbor Pat, but she soon becomes Pat and Denise's closest friend in the neighborhood and enthusiastically helps them in a few schemes. Robert Curtis Brown as Principal Horner, the principal at Ridgewood High School. He becomes at odds with Pat and Janelle when he makes racist assumptions during a meeting with them. Denise recognizes him at a PTO meeting from when he offered her a threesome on Christian Mingle. Lindsey Pearlman as Martha, Principal Horner's assistant at Ridgewood High School. She struggles to adapt to black culture and mistakes Janelle's name as "Janeesha" and "Janiqua." At a PTO meeting, fellow participant Elizabeth reveals that Martha has a criminal record. Martha was one of actress Lindsey Pearlman's last roles before her death in 2022. Gavin Bedell as Ryan Patterson, one of Junebug's friends. He is the son of the PTO chair and first appears on the scene when enlisted to help Junebug with one of Ms. Pat's schemes. Nicholas Ryan Hernandez as Sergio, another of Junebug's friends.
Biotextiles are specialized materials engineered from natural or synthetic fibers. These textiles are designed to interact with biological systems, offering properties such as biocompatibility, porosity, and mechanical strength or are designed to be environmentally friendly for typical household applications. There are several uses for biotextiles since they are a broad category. The most common uses are for medical or household use. However, this term may also refer to textiles constructed from biological waste products. These biotextiles are not typically used for industrial purposes. The term "biotextiles" derives from the combination of "bio," referring to biology or living organisms, and "textiles," indicating woven or fibrous materials. It encompasses the interdisciplinary field of biomedical textiles, which focuses on the design, fabrication, and application of textile materials in healthcare and biomedical engineering. Biotextiles made from mycelium, vegetable biomass, bacterial cellulose, and recombinant protein based fibers are used as an alternative to synthetic textiles to prevent and reduce the high greenhouse gas emissions, water pollution, and landfill waste from the textile industry. Biotextiles are also used within healthcare and the biomedical engineering field as implantable devices such as surgical sutures, hernia repair fabrics, arterial grafts, artificial skin and parts of artificial hearts.
The U.S. Institute of Medicine (renamed National Academy of Medicine in 2015) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for niacin in 1998, as well as Tolerable upper intake levels (ULs). In lieu of an RDA, Adequate Intakes (AIs) are identified for populations for which there is not enough evidence to identify a dietary intake level that is sufficient to meet the nutrient requirements of most people. (see table). The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values (DRV), with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. For the EU, AIs and ULs have the same definition as in the US, except that units are milligrams per megajoule (MJ) of energy consumed rather than mg/day. For women (including those pregnant or lactating), men and children the PRI is 1.6 mg per megajoule. As the conversion is 1 MJ = 239 kcal, an adult consuming 2390 kilocalories should be consuming 16 mg niacin. This is comparable to US RDAs (14 mg/day for adult women, 16 mg/day for adult men). ULs are established by identifying amounts of vitamins and minerals that cause adverse effects, and then selecting as an upper limit amounts that are the "maximum daily intake unlikely to cause adverse health effects". Regulatory agencies from different countries do not always agree. For the US, 30 or 35 mg of niacin for teenagers and adults, less for children.
Reptiles endemic to Somalia include the Hughes' saw-scaled viper, the Southern Somali garter snake, a racer (Platyceps messanai), a diadem snake (Spalerosophis josephscorteccii), the Somali sand boa, the angled worm lizard, a spiny-tailed lizard (Uromastyx macfadyeni), Lanza's agama, a gecko (Hemidactylus granchii), the Somali semaphore gecko, and a sand lizard (Mesalina or Eremias). A colubrid snake (Aprosdoketophis andreonei) and Haacke-Greer's skink (Haackgreerius miopus) are endemic species.
Sources: en.wikipedia.org
== Efficacy == The COVID-19 mRNA vaccines from Moderna and Pfizer–BioNTech had short-term efficacy rates of over 90 percent against the original SARS-CoV-2 virus. Prior to mRNA, drug trials on pathogens other than COVID-19 were not effective and had to be abandoned in the early phases of trials. The reason for the efficacy of the new mRNA vaccines is not clear. Physician-scientist Margaret Liu stated that the efficacy of the new COVID-19 mRNA vaccines could be due to the "sheer volume of resources" that went into development, or that the vaccines might be "triggering a nonspecific inflammatory response to the mRNA that could be heightening its specific immune response, given that the modified nucleoside technique reduced inflammation but hasn't eliminated it completely", and that "this may also explain the intense reactions such as aches and fevers reported in some recipients of the mRNA SARS-CoV-2 vaccines". These reactions though severe were transient and another view is that they were believed to be a reaction to the lipid drug delivery molecules. In June 2021, the US Food and Drug Administration added a warning about the possibility of increased risk of myocarditis and pericarditis for some people.
=== Antiquity === The presence and diseases of the thyroid have been noted and treated for thousands of years. In 1600 BCE burnt sponge and seaweed (which contain iodine) were used within China for the treatment of goitres, a practice which has developed in many parts of the world. In Ayurvedic medicine, the book Sushruta Samhita written about 1400 BCE described hyperthyroidism, hypothyroidism and goitre. Aristotle and Xenophon in the fifth century BCE describe cases of diffuse toxic goitre. Hippocrates and Plato in the fourth century BCE provided some of the first descriptions of the gland itself, proposing its function as a salivary gland. Pliny the Elder in the first century BCE referred to epidemics of goitre in the Alps and proposed treatment with burnt seaweed, a practice also referred to by Galen in the second century, referred to burnt sponge for the treatment of goitre. The Chinese pharmacology text Shennong Ben Cao Jing, written ca. 200–250, also refers to goitre.
=== Conference === WOSM's conference is its general meeting of member organizations' representatives which meet every three years, hosted by a member association. Each member organizations may send six delegates. The conference is usually preceded by the World Scout Youth Forum.
Copper(II) salts have an LD50 of 100 mg/kg. Copper(II) sulfate was used in the past as an emetic. It is now considered too toxic for this use. It is still listed as an antidote in the World Health Organization's Anatomical Therapeutic Chemical Classification System.
=== DuPont and the invention of nylon === Researchers at DuPont began developing cellulose-based fibers, culminating in the synthetic fiber rayon. DuPont's experience with rayon was an important precursor to its development and marketing of nylon. DuPont's invention of nylon spanned an eleven-year period, ranging from the initial research program in polymers in 1927 to its announcement in 1938, shortly before the opening of the 1939 New York World's Fair. The project grew from a new organizational structure at DuPont, suggested by Charles Stine in 1927, in which the chemical department would be composed of several small research teams that would focus on "pioneering research" in chemistry and would "lead to practical applications". Harvard instructor Wallace Hume Carothers was hired to direct the polymer research group. Initially he was allowed to focus on pure research, building on and testing the theories of German chemist Hermann Staudinger. He was very successful, as research he undertook greatly improved the knowledge of polymers and contributed to the science. Nylon was the first commercially successful synthetic thermoplastic polymer. DuPont began its research project in 1927. The first nylon, nylon 66, was synthesized on February 28, 1935, by Wallace Hume Carothers at DuPont's research facility at the DuPont Experimental Station. In response to Carothers' work, Paul Schlack at IG Farben developed nylon 6, a different molecule based on caprolactam, on January 29, 1938. In the spring of 1930, Carothers and his team had already synthesized two new polymers.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.
The fatty diacid chain associates strongly with serum albumin, which keeps the peptide in circulation and shields it from rapid renal clearance. Bound peptide is released gradually, producing a sustained receptor signal. This mechanism also reduces the peak-to-trough variation seen with shorter-acting analogues.
The balance between peripheral receptor activation and signalling in the central nervous system is not fully resolved. The extent to which slowed gastric emptying accounts for reduced energy intake, compared with direct effects on appetite circuits, is debated. Long-term effects on lean mass and on tissues outside the gut and brain are still under study.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.